Case report of acute type 2 respiratory failure secondary to Colistin
Keywords:
Colistin, neurotoxicity, respiratory failureAbstract
We report an elderly patient who developed type 2 respiratory failure after receiving Colistimethate (CMT). The patient has chronic kidney disease, and was admitted to Medical Intensive Care Unit with pneumococcal pneumonia. However, he had nosocomial acinetobacter baumannii urinary tract infection, which was only sensitive to colistin. Unfortunately, 72 hours after initiation of Colistimethate, his consciousness deteriorated. 5 days later, he passed into acute type 2 respiratory failure. All investigations were done and no cause was found so, Colistin induced respiratory failure was presumed hence, the drug was withdrawn, and his condition improved within 48 hours and was extubated 4 days later.
References
1- Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 723-63.
2- Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K: A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot 1950; 457-58.
3- Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;1333–41.
4- Zhiliang Yu , Yuanning Cai, Wangrong Qin, Polymyxin E Induces Rapid Paenibacillus polymyxa Death by Damaging Cell Membrane while Ca2+ Can Protect Cells from Damage. PLoS One. 2015; 10(8)
5- Evans ME, Feola DJ, Rapp RP. PolymyxinB sulfate and colistin: old antibiotics for emerging multi resistant Gram-negative bacteria. Ann. Pharmacother. 1999, 960–67.
6- Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 535–43.
7- Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A3rd et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;1279–91.
8-Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 857–68.
9-Parisi AF, Kaplan MH. Apnea during treatment with sodium colistimethate. JAMA. 1965;298–99.
10-McQuillen MP, Cantor HA, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Trans Am Neurol Assoc. 1967;163–67.
11-Falagas ME, Kasiakou SK. Toxicity of polymyxins: a system- atic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
12-Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med. 1968;318-27.
13-Wahby K, Chopra T, Chandrasekar P. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis. 2010; 38-40.
14-Spapen HD, Honore PM, Gregoire N, et al. Convulsions and apnoea in a patient infected with New Delhi metallo-beta- lactamase-1 Escherichia coli treated with colistin. J Infect. 2011; 468-70.
15-Wunsch H, Moitra VK, Patel M, Dzierba AL. Polymyxin use associated with respiratory arrest. Chest. 2012; 515-17.
16-Fernandez AB, Perez M, Soto L. Sudden respiratory muscle paralysis and apnea in a patient infected with multidrug-resis- tant Pseudomonas aeruginosa treated with intravenous colis- tin. Int J Infect Dis. 2013;357.
17-Wadia S, Tran B. Colistin-mediated neurotoxicity. BMJ Case Rep. 2014;2014.
18-Shrestha A, Soriano SM, Song M, Chihara S. Intravenous colistin-induced acute respiratory failure: a case report and a review of literature. Int J Crit Illness Inj Sci. 2014; 266-70.
19-Nigam A, Kumari A, Jain R, Batra S. Colistin neurotoxicity: revisited. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2015- 210787.
2- Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K: A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot 1950; 457-58.
3- Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;1333–41.
4- Zhiliang Yu , Yuanning Cai, Wangrong Qin, Polymyxin E Induces Rapid Paenibacillus polymyxa Death by Damaging Cell Membrane while Ca2+ Can Protect Cells from Damage. PLoS One. 2015; 10(8)
5- Evans ME, Feola DJ, Rapp RP. PolymyxinB sulfate and colistin: old antibiotics for emerging multi resistant Gram-negative bacteria. Ann. Pharmacother. 1999, 960–67.
6- Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 535–43.
7- Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A3rd et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;1279–91.
8-Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 857–68.
9-Parisi AF, Kaplan MH. Apnea during treatment with sodium colistimethate. JAMA. 1965;298–99.
10-McQuillen MP, Cantor HA, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Trans Am Neurol Assoc. 1967;163–67.
11-Falagas ME, Kasiakou SK. Toxicity of polymyxins: a system- atic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
12-Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med. 1968;318-27.
13-Wahby K, Chopra T, Chandrasekar P. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis. 2010; 38-40.
14-Spapen HD, Honore PM, Gregoire N, et al. Convulsions and apnoea in a patient infected with New Delhi metallo-beta- lactamase-1 Escherichia coli treated with colistin. J Infect. 2011; 468-70.
15-Wunsch H, Moitra VK, Patel M, Dzierba AL. Polymyxin use associated with respiratory arrest. Chest. 2012; 515-17.
16-Fernandez AB, Perez M, Soto L. Sudden respiratory muscle paralysis and apnea in a patient infected with multidrug-resis- tant Pseudomonas aeruginosa treated with intravenous colis- tin. Int J Infect Dis. 2013;357.
17-Wadia S, Tran B. Colistin-mediated neurotoxicity. BMJ Case Rep. 2014;2014.
18-Shrestha A, Soriano SM, Song M, Chihara S. Intravenous colistin-induced acute respiratory failure: a case report and a review of literature. Int J Crit Illness Inj Sci. 2014; 266-70.
19-Nigam A, Kumari A, Jain R, Batra S. Colistin neurotoxicity: revisited. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2015- 210787.
Downloads
Published
2020-01-19
How to Cite
1.
Algherbawe M, Wanis AW. Case report of acute type 2 respiratory failure secondary to Colistin. Iraq Med J [Internet]. 2020 Jan. 19 [cited 2024 Nov. 25];3(3). Available from: https://mail.iraqmedj.org/index.php/imj/article/view/647
Issue
Section
Case Report